方法对比

	特应性皮炎评分指数（SCORAD）	EASI（湿疹面积与严重程度指数）	POEM（患者导向的湿疹评估量表）	瘙痒视觉模拟评分法 (Pruritus VAS)
领域	皮肤病学	皮肤病学	皮肤病学	皮肤病学
方法族	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
起源年份	1993	2001	2004	1983 (VAS); widely adopted for pruritus 1990s–2000s
提出者	European Task Force on Atopic Dermatitis (ETFAD)	Hanifin JM, Thurston M	Charman CR, Venn AJ, Williams HC	Huskisson EC (VAS methodology); adapted for pruritus in dermatology
类型	Clinician-rated	Clinician-rated	Self-report	Self-report
开创性文献	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.	Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587-593.
别名	SCORAD Index	EASI Index	POEM Score	Itch VAS, Pruritus Severity Scale
相关	3	2	2	3
摘要	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.	The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA).	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	The Pruritus Visual Analog Scale (VAS) is a simple, single-item patient-administered tool measuring itch intensity on a continuous 0–10 (or 0–100) scale. Adapted from the original VAS for pain, it is one of the most frequently used outcome measures in dermatological research and clinical practice due to its simplicity, brevity, and responsiveness to treatment. Pruritus VAS is essential in trials of antipruritic therapies and in conditions where itching is a primary complaint (atopic dermatitis, psoriasis, pruritus ani, lichen planus).